Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
VERU - Veru Inc
-0.77(-7.92%)9:00:00 PM 1/15/2021
Veru Inc., an oncology biopharmaceutical company, engages in developing medicines for prostate cancer treatment and prostate cancer supportive care. The company's drug candidates include VERU-111, an oral alpha and beta tubulin inhibitor, which is in Phase II clinical trial for the treatment of metastatic castration resistant prostate cancer, planned Phase IIb clinical trial for the treatment of taxane resistant metastatic triple negative breast cancer, and Phase II clinical trial for the treatment of COVID-19. Its drug candidates also include Zuclomiphene citrate, which has completed Phase II clinical trial for the treatment of hot flashes in men with advanced prostate cancer; VERU-100, a GnRH antagonist that is in planned Phase II clinical trial for the palliative treatment of advanced prostate cancer; Enobosarm, a selective androgen receptor agonist that is in planned Phase III registration study for the treatment of metastatic breast cancer; and TADFYN, a tadalafil and finasteride combination capsules for the treatment of men with lower urinary tract symptoms. Additionally, the company's commercial products include the FC2 Female/Internal condoms for the prevention of pregnancy and sexually transmitted infections. Its customers primarily include international agencies, government health agencies, ministries of health, and other governmental agencies, which purchase and distribute FC2 for use in HIV/AIDS prevention and family planning programs; and telemedicine providers who sell into the prescription channel in the United States. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Stock Chart
No summary

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics

Related Peers

Stock news

    Veru to Present at the H.C. Wainwright Bioconnect 2021 Conference on January 11th, 2021

    MIAMI, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the H.C. Wainwright Bioconnect 2021 Conference. The presentation will be available on-demand through the Conference from January 11-14, 2021 starting at 6:00 a.m. ET. A webcast of the presentation will also be available at

    If You Had Bought Veru (NASDAQ:VERU) Stock Three Years Ago, You Could Pocket A 615% Gain Today

    Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. You won't get...

    Veru Stock Jumps 207% in One Week — How Much Higher Can It Go?

    Not many sectors offer the potential for big time gains like biotech. Especially when you’re looking at smaller clinical-stage names. Case in point: Veru (VERU) stock has been on one almighty run since announcing an expansion of its oncology drug pipeline last Wednesday; shares have surged 207% in the interim.Specifically, the company has exclusively licensed worldwide rights to enobosarm - an androgen receptor targeting agent for endocrine resistant metastatic breast cancer.The latest leg up to...

    Implied Volatility Surging for Veru (VERU) Stock Options

    Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.

    Biotech Veru's Treatment Could Be a Game Changer, but What About the Stock?

    For his second "Executive Decision" segment of Mad Money Monday evening, Jim Cramer spoke with Dr. Mitchell Steiner, chairman, president and CEO of Veru , a biotech leading a charge against breast and prostate cancer. Steiner explained that Veru's goal is to change the standard of care for patients diagnosed with breast or prostate cancer.

    Looking Into Veru's Return On Capital Employed

    During Q4, Veru's (NASDAQ: VERU) reported sales totaled $11.75 million. Despite a 709.11% in earnings, the company posted a loss of $11.27 million. Veru collected $10.32 million in revenue during Q3, but reported earnings showed a $1.39 million loss.What Is Return On Capital Employed? Changes in earnings and sales indicate shifts in Veru's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth...

    Do Options Traders Know Something About Veru (VERU) Stock We Don't?

    Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.

    Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer

    \-- Phase 2 Multicenter, International Clinical Study Selected as Spotlight Presentation at 2020 San Antonio Breast Cancer Symposium –\--Enobosarm Demonstrated Clinically Meaningful Clinical Benefit Rates, Overall Response Rates, Median Radiographic Progression-Free Survival and Well Tolerated Safety Profile in Heavily Pretreated Endocrine and Chemotherapy Resistant Metastatic Breast Cancer Cohorts-- \--FDA Agrees to Phase 3 Clinical ARTEST Study for the Treatment of Endocrine Resistant ER+/H...

    VERU-111, Cytoskeleton Disruptor, Demonstrates Efficacy in Preclinical Models of Human Triple Negative Breast Cancer

    \-- Preclinical Data Presented at the 2020 San Antonio Breast Cancer Symposium-- \-- VERU-111 has Anticancer Activity in Both Paclitaxel Sensitive and Paclitaxel Resistant Triple Negative Breast Cancer Tumors-- \--Veru Plans to Meet with FDA and Advance VERU-111 into a Phase 2b Clinical Trial in Women with Paclitaxel Resistant Triple Negative Breast Cancer in 2021--MIAMI, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on develop...